Access to special care dentistry, part 5. Safety

British Dental Journal

Volumn 205, Issue 4, 2008, Pages 177-190

  Dougall, A ^a   Fiske, J ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ALLERGY; ANAMNESIS; BLOOD CLOTTING DISORDER; DENTAL CARE; DOCTOR PATIENT RELATION; EPILEPSY; HEALTH CARE DELIVERY; HUMAN; INTERPERSONAL COMMUNICATION; METHODOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT CARE PLANNING; REVIEW; RISK ASSESSMENT; SAFETY;

BLOOD COAGULATION DISORDERS; BONE DENSITY CONSERVATION AGENTS; DENTAL CARE FOR CHRONICALLY ILL; DENTAL CARE FOR DISABLED; DENTIST-PATIENT RELATIONS; DIPHOSPHONATES; DISCLOSURE; EPILEPSY; HEALTH SERVICES ACCESSIBILITY; HUMANS; LATEX HYPERSENSITIVITY; MEDICAL HISTORY TAKING; PATIENT CARE PLANNING; PATIENT-CENTERED CARE; RISK ASSESSMENT; SAFETY;

EID: 50149085585     PISSN: 00070610     EISSN: 17417503     Source Type: Journal    
DOI: 10.1038/sj.bdj.2008.693     Document Type: Review

References (72)

1. Fiske J, Boyle C. Epilepsy and dental care. Dent Update 2002; 4: 180-187.
2. Heaney D, Macdonald B, Everitt A et al. Socioeconomic variation in incidence of epilepsy; prospective community based study in South East England. BMJ 2002; 325: 1013-1016.
3. Sanders B, Weddell J, Dodge N. Managing patients who have seizure disorders; dental and medical issues. J Am Dent Assoc 1995; 126: 1641-1647.
4. Scully C, Cawson R. Neurological disorders. In Medical problems in dentistry. Chapter 17. Oxford: Wright, 1999.
5. Scully C, Dios P D, Kumar N. Special care in dentistry: handbook of oral healthcare. pp 171-177. Edinburgh: Churchill Livingstone, 2007.
6. Sander J, Hart Y. Epilepsy: questions and answers. pp 43-51. Hampshire: Merit Publishing International, 1999.
7. British National Formulary 55. London: BMJ Publishing Group and RPS Publishing, 2008.
8. Sander J W. The incidence and prevalence of epilepsy. In Sander J W, Walker M C, Smalls J E (eds) Epilepsy 2007: from cell to community, a practice guide to epilepsy. pp 1-6. Chalfont: National Society for Epilepsy and International League Against Epilepsy, 2007. www.e-epilepsy.org.uk
9. Prasad V N, Chawla H S, Goyal A, Gauba K, Singhi P. Incidence of phenytoin induced gingival overgrowth in epileptic children: a six month evaluation. J Indian Soc Pedod Prev Dent 2002; 20: 73-80.
10. Stinnett E, Rodu B, Grizzle W. New development in understanding phenytoin induced gingival hyperplasia. J Am Dent Assoc 1987; 114: 814-816.
11. Guncu G N, Caglayan F, Dincel A, Bozkurt A, Saygi S, Karabulut E. Plasma and gingival crevicular fluid phenytoin concentrations as risk factors for gingival overgrowth. J Periodontol 2006; 77: 2005-2010.
12. Lafzi A, Farahani R, Shoja M. Phenobarbital-induced gingival hyperplasia. J Contemp Dent Pract 2007; 8: 50-56.
13. Majola M P, McFadyen M L, Connolly C, Nair Y P, Govender M, Laher M H. Factors influencing phenytoin-induced gingival enlargement. J Clin Periodontol 2000; 27: 506-512.
14. Seymour R, Ellis J, Thomason J. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000; 27: 217-223.
15. Dahllof G, Axio E, Modeer T. Regression of phenytoin-induced ginigval overgrowth after withdrawl of medication. Swed Dent J 1991; 15: 139-143.
16. Pick L, Bauer J. Dentistry and epilepsy. Nervenarzt 2001; 72: 946-949.
17. Dougall A, Fiske J. Access to special care dentistry, part 4. Education. Br Dent J 2008; 205: 119-130.
18. Mackie I. Doctors must take the lead by prescribing sugar free medicines whenever possible. BMJ 1995; 311: 141-142.
19. Buck D, Baker G, Jacoby A, Smith D, Chadwick D. Patients' experiences of injury as a result of epilepsy. Epilepsia 1997; 38: 439-444.
20. Radnai M, Szontágh E, Fazekas A. Prosthetic rehabilitation of an epilepsy patient with dental implants. Case report. Fogorv Sz 2006; 99: 121-124.
21. Rood J. Local anaesthesia and the medically compromised patient. Dent Update 1991; 18: 330-334.
22. Dougall A. Sedation and special care dentistry. Dental Sedation Teachers Group Annual Meeting, Birmingham, 2007.
23. Robb N, Hargrave S. Tolerance to intravenous midazolam as a result of oral benzodiazepine therapy, a potential problem for the provision of conscious sedation in dentistry. Anesth Pain Control Dent 1993; 2: 94-97.
24. Manley G, Skelly M. The use of sedation in the treatment of people with disability. In Nunn J (ed) Disability and oral care. Chapter 10. London: FDI World Press, 2000.
25. Hickey K, Martin D, Chuidian F. Propofol-induced seizure-like phenomena. J Emerg Med 2005; 4: 447-449.
26. National Institute for Clinical Excellence. The epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: NICE, 2004. Clinical guideline 20. www.nice.org.uk/guidance
27. Walker M C. Treatment of non-convulsive status epilepticus. In Sander J W, Walker M C, Smalls J E (eds) Epilepsy 2007: from cell to community, a practice guide to epilepsy. pp 317-322. Chalfont: National Society for Epilepsy and International League Against Epilepsy, 2007. www.e-epilepsy.org.uk
28. Heafield M T E. Managing status epilepticus. BMJ 2000; 320: 953-954.
29. Behrman A J, Howarth M. Latex allergy. eMedicine online article, http://www.emedicine.com/emerg/topic814.htm (accessed 7 July 2008).
30. Latex Allergy Support Group website. 2007. www.lasg.co.uk/
31. Longman L. Rubber trouble. Irish Society for Disability and Oral Health Summer Conference 2007, Tullamore, Ireland.
32. Clark A. The provision of dental care for patients with natural rubber latex allergy: are patients able to obtain safe care? Br Dent J 2004; 197: 749-752.
33. Faculty of General Dental Practice (UK). Guidance for the management of natural rubber latex allergy in dental patients and dental healthcare workers. London: FGDP(UK), 2004.
34. Field E, Longman L, Sharkawi M, Perrin L, Davies M. The dental management of patients with natural rubber latex allergy. Br Dent J 1998; 185: 65-69.
35. Field E, Fay M. Issues of latex safety in dentistry. Br Dent J 1995; 179: 247-253.
36. Kelly K, Pearson M, Kurup V. Anaphalactic reactions in patients with spina bifida during general anaesthesia. J Allergy Clin Immunol 1994; 93: 813-816.
37. Kamm M. Faecal incontinence. BMJ 1998; 316: 528-532.
38. Resuscitation Council UK. Emergency treatment of anaphylactic reactions. Guidelines for healthcare providers. London: Resuscitation Council UK, 2008. www.resus.org.uk/pages/reaction.pdf
39. Resuscitation Council UK. Frequently asked questions on 'Emergency treatment of anaphylactic reactions. Guidance for healthcare providers'. London: Resuscitation Council UK, 2008. www.resus.org.uk/pages/faqAna.htm
40. Ruggiero S. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007; 86: 1013-1021.
41. Woo S-B, Hellstein J W, Kalmar J R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761.
42. American Dental Association. Dental management of patients receiving oral bisphosphonate therapy - expert panel recommendations. J Am Dent Assoc 2006; 137: 1144-1150.
43. World Health Organization. WHO scientific group on the assessment of osteoporosis at the primary health care level. Summary meeting report. Geneva: World Health Organization, 2007. http://www.who.int/chp/topics/ Osteoporosis.pdf
44. National Osteoporosis Society website. www.nos.org.uk (accessed 8 July 2008).
45. McMahon R E, Bouquot J E, Glueck C J et al. Staging bisphosphonate-related osteonecrosis of the jaw should include early stages of disease. J Oral Maxillofac Surg 2007; 65: 1899-1900.
46. Migliorati C, Casiglia J, Epstein J, Jacobsen P, Siegel M. Managing the care of patients with bisphosphonate associated osteonecrosis. J Am Dent Assoc 2005; 136: 1658-1668.
47. Anon. Bisphosphonate therapy and osteonecrosis of the jaws. Contemporary Oral Hygiene 2006; December: http://www. contemporaryoralhygieneonline.com/issues/articles/2006-12_10.asp
48. Cramer J, Lynch N, Gaudin A, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in post-menopausal women in the United States, United Kingdom and France. Clin Ther 2006; 10: 1686-1694.
49. Barker K, Rogers S. Bisphosphonate-associated osteonecrosis of the jaws - a guide for the general dental practitioner. Dent Update 2006; 33: 270-272.
50. American Association of Endodontists. AAE position statement. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws. Chicago: American Association of Endodontists, 2006. http://www.aae.org/dentalpro/EducationalResources/guidelines.htm
51. Kearns G. BRONJ - the bisphosphonate story for the ageing population. Irish Society for Disability and Oral Health Winter Meeting, Dublin. November 2007.
52. Lane N. Long-term effects of treatment with alendronate for patients with osteoporosis. Nat Clin Pract Rheumatol 2007; 3: 426-427.
53. Rafique S. Managing patients with bleeding disorders. In Fiske J, Dickinson C, Boyle C, Rafique S, Burke M Special care dentistry. pp 103-114. London: Quintessence Publishing, 2007.
54. Lockhart P B, Gibson J, Pond S H, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 1: coagulopathies from systemic disease. Br Dent J 2003; 195: 439-445.
55. Randall C (ed). Surgical management of the primary care dental patient on antiplatelet medication. Liverpool: North West Medicines Information Centre, 2007. http://www.druginfozone.nhs.uk/Record%20Viewing/viewRecord.aspx? id=582288
56. Randall C (ed). Surgical management of the primary care dental patient on warfarin. Liverpool: North West Medicines Information Centre, 2007. http://www.druginfozone.nhs.uk/Record%20Viewing/viewRecord.aspx?id=582287
57. Richards S. Guidelines for the management of patients who are taking oral anticoagulants and who require dental surgery. Evid Based Dent 2008; 9: 5-6.
58. Gomez-Moreno G, Cutando-Soriano A, Arana C, Scully C. Hereditary blood coagulation disorders: management and dental treatment. J Dent Res 2005; 84: 978-985.
59. Brewer A, Correa M. Guidelines for dental treatment of patients with inherited bleeding disorders. Montreal: World Federation of Hemophilia, 2006. Treatment of Hemophilia Monograph no. 40.
60. Brewer A, Roebuck E, Donachie M et al. The dental management of adult patients with haemophilia and other congenital bleeding disorders. Hemophilia 2003; 9: 673-677.
61. Stubbs M, Lloyd J. A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B. Aust Dent J 2001; 46: 37-40.
62. Fiske J, Pitt Ford H, Savidge G, Smith M. The expressed dental needs of patients attending a haemophilia reference centre. J Disabil Oral Health 2000; 1: 20-25.
63. Harrington B. Primary care of patients with haemophilia. Hemophilia 2000; 6(Suppl): 7-12.
64. White G C 2nd, Rosendaal F, Aledort L M et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
65. The Haemophilia Society. Information fact sheet. von Willebrand's: general information. London: The Haemophilia Society, 2003. http://www.haemophilia.org.uk/uploads/vwillebrandsgeneral.pdf
66. Lee A, Boyle C, Savidge G, Fiske J. Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. Br Dent J 2005; 198: 33-38.
67. Fried M. Management of hepatitis C in the haemophilia patient. Am J Med 1999; 107: 855-895.
68. Eyster M E, Diamondstone L S, Lien J M, Ehmann W C, Quan S, Goedert J J. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602-610.
69. Gupta A, Epstein J, Cabay R. Bleeding disorders of importance in dental care and related patient management. J Can Dent Assoc 2007; 73: 77-83.
70. Meechan J G, Greenwood M. General medicine and surgery for dental practitioners. Part 9: haematology and patients with bleeding problems. Br Dent J 2003; 195: 305-310.
71. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-386.
72. Robertson D, Nusstein J, Reader A, Beck M, McCartney M. The anesthetic efficacy of articaine in buccal infiltration of mandibular posterior teeth. J Am Dent Assoc 2007; 138: 1104-1112.